Did “Medicus economicus” Kill Medicare Part B Reform?

By DAVID, MATTHEWS and MAUGHN When doctors complain about proposed changes to health care reimbursement, do they speak for patients or their pocketbooks? As the recent debate over Medicare Part B shows, even with access to publicly available billing data, it's hard to disentangle financial motivations from more altruistic ones. Since 2005, Medicare Part B has paid for physician-administered drugs like infused chemotherapeutics by reimbursing 106% of the average selling price (ASP) – a formula commonly referred to as "ASP+6". In order to reduce overall spending and the program's apparent incentive for physicians to preferentially use high-priced drugs, CMS proposed a pilot program last year to test a new payment formula that would have reduced the 6% markup to 2.5%, but added a...

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.

from MedWorm via o.lakala70 on Inoreader http://ift.tt/2sjgRoH
via IFTTT